If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Baricitinib
Olumiant ® (baricitinib) tablets
1mg, 2mgThis information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Olumiant Prescribing Information
See important safety information, including boxed warning, in the attached prescribing information.
Dosing Considerations in Patients with Rheumatoid Arthritis
The recommended dose of BARI is 2mg once daily for patients with moderately to severely active RA who have had an inadequate response to one or more TNF antagonist therapies.1
In patients with moderate renal impairment (estimated glomerular filtration rate between 30 and 60 mL/min/1.73 m2), the recommended dose of BARI is 1 mg once daily. 1
In patients taking strong OAT3 inhibitors, such as probenecid, the recommended dose of OLUMIANT is 1 mg once daily.1
Limitations of Use
Use of BARI is not recommended in patients with
severe renal impairment (estimated glomerular filtration rate <30 mL/min/1.73m2)
severe hepatic impairment
active, serious infection, including localized infections
absolute lymphocyte count <500 cells/mm3
absolute neutrophil count <1000 cells/mm3, or
hemoglobin level <8 g/dL.1
Route of Administration
The appropriate dose of BARi is given orally once daily.1
Food Effects
Administration with meals is not associated with a clinically relevant effect on exposure.1
An assessment of food effects in healthy subjects showed that a high-fat meal decreased the mean area under the curve and maximum serum concentration of BARI by approximately 11% and 18%, respectively, and delayed the time to reach maximum serum concentration by 0.5 hours.1
In clinical studies, BARI was administered without regard to meals.1
Timing
Baricitinib can be taken at any time of day or night. It is best to take BARI at the same time every day.1,2
Use With Other RA Therapies
Baricitinib may be used as monotherapy or in combination with MTX or other DMARDs.1
Use of BARI is not recommended in combination with
other Janus kinase inhibitors
biologic DMARDs, or
potent immunosuppressents, such as azathioprine and cyclosporine.1
Enclosed Prescribing Information
OLUMIANT® (baricitinib) tablets, for oral use, Lilly
1. Olumiant [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.
2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Glossary
BARI = baricitinib
DMARD = disease-modifying antirheumatic drug
MTX = methotrexate
OAT = organic anion transporter
Date of Last Review: October 07, 2019
If you have immediate questions regarding COVID-19, or to report an Adverse Event or Product Complaint, please call us.
Daily Live Support: 9am to 7pm ET.
After Hours: Call Back Support Available